
Tim Bergreen
Articles
-
Jan 14, 2025 |
jdsupra.com | Tim Bergreen |Anthony Capobianco |Brian Curran
The rule regulates transactions involving access to (1) U.S. government-related data and (2) bulk sensitive personal data. While those categories may appear narrow, they are actually quite broad in a manner that will pick up ordinary data flows for many multinational companies.
-
Nov 18, 2024 |
jdsupra.com | Michael Bell |Tim Bergreen |Neil Chatterjee
Former President Donald Trump has achieved a resounding and historic political comeback, reclaiming the White House four years after his 2020 defeat to President Joe Biden. Now set to serve as the 45th and 47th President, Trump surpassed his 2016 peormance by sweeping all seven swing states and becoming the rst Republican President in 20 years to win the popular vote. Please see full publication below for more information.
-
Nov 13, 2024 |
jdsupra.com | Tim Bergreen |Anthony Capobianco |Brian Curran
The NPRM aims to restrict the ability of designated countries of concern and persons subject to their jurisdiction (“covered persons”) to access U.S. government-related data or bulk sensitive personal data by restricting or prohibiting certain transactions. There are six countries of concern that the NPRM identifies: China (including Hong Kong and Macau), Cuba, Iran, North Korea, Russia, and Venezuela.
-
Nov 12, 2024 |
hoganlovells.com | Tim Bergreen |Anthony Capobianco |Brian Curran |Scott Loughlin
The U.S. remains on course to restrict a broad range of cross border data transfers to China, Russia, and other designated countries. On October 21, 2024, the Department of Justice (DOJ) issued a Notice of Proposed Rulemaking (NPRM) (and an accompanying Fact Sheet) intended to address national security concerns regarding certain countries and persons subject to their jurisdiction.
-
May 22, 2024 |
jdsupra.com | Tim Bergreen |Michael Druckman |Ajay Kuntamukkala
While the landscape continues to evolve rapidly, there are steps that life sciences companies – particularly cell, tissue, and gene therapy (CTGT) and other companies engaged in complex biotechnology manufacturing – should consider taking now to avoid unintended and potentially serious consequences if (/when) the pending legislation is enacted.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →